

Table 1 Ongoing Trials of Preventive HIV/AIDS Vaccines Worldwide (May 2009)

Protocol #	Start Date	Sponsor, Funder, Developer	Trial Site(s)	# of Participants	Vaccine(s)	Clade
PHASE III						
RV 144	Oct-03	MHRP, MoPH Thailand, Aventis, Vaxgen	Thailand	16,402	Prime: canarypox viral vector with <i>env</i> and <i>gag-pol</i> Boost: <i>Env</i> protein (gp120 subunits)	B A/E
TEST-OF-CONCEPT						
The two trials that follow, HVTN 503 and 502, stopped enrollment and immunizations, September 2007. Follow-up and data collection continue. For more information visit: http://avac.org/vax_update.htm .						
HVTN 503 (Phambili)	Feb-07	SAAVI, HVTN	South Africa	801	Adenovirus vector with <i>gag, pol, nef</i>	B
HVTN 502/ Merck 023 (Step study)	Dec-04	NIAID, HVTN, Merck	US, Canada, Peru, Dominican Republic, Haiti, Puerto Rico, Australia, Brazil, Jamaica	3,000	Adenovirus vector with <i>gag, pol, nef</i>	B
PHASE II						
HVTN 205	Jan-09	GeoVax, HVTN	US, Peru	225	Prime: DNA vaccine containing <i>gag, pol, env, rat, rev, vpu</i> Boost: MVA vaccine containing <i>gag, pol, env</i>	B
PHASE I / II						
EV 03/ANRS Vac20	June-07	European Commission, ANRS	UK, Germany, Switzerland, France	140	Prime: DNA vaccine with <i>env</i> plus <i>gag, pol, nef</i> Boost: NYVAC-C	C
HIVIS 03	Dec-06	MUCHS, Karolinska Institute, SMI, Vecura, MHRP	Tanzania	60	Prime: HIVIS DNA with <i>env, gag, rev, RT</i> Boost: MVA-CMDR with <i>env, gag, pol</i>	A, B, C A, E
RV 172	May-06	NIH, MHRP, VRC	Kenya, Uganda, Tanzania	324	Prime: DNA vaccine with <i>gag, pol, nef + env</i> Boost: Adenovirus vector with <i>gag, pol + env</i>	B A, B, C
PHASE I						
B001	Mar-09	IAVI, University of Rochester Medical Center	US	42	Adenovirus serotype 35 vector. Ad35-GRIN/ENV consists of two vectors: Ad35-GRIN vector with <i>gag</i> , reverse transcriptase, integrase, and <i>nef</i> Ad35-ENV vector with gp140 <i>env</i>	A
P001	Mar-09	IAVI, Indian Council of Medical Research	India	32	Prime: ADVAX (DNA vaccine containing <i>env, gag, pol, nef and tat</i>) Boost: TBC-M4 (MVA vector with <i>env, gag, RT, rev, tat and nef</i>)	C
P002	Dec-08	IAVI, St. Stephen's AIDS trust, Chelsea and Westminster Hospital	UK	32	Prime: ADVAX (DNA vaccine containing <i>env, gag, pol, nef and tat</i>) Boost: TBC-M4 (MVA vector with <i>env, gag, RT, rev, tat and nef</i>)	C
HVTN 073	Dec-08	HVTN, SAAVI	US, South Africa	48	Prime: SAAVI DNA-C2 Boost: SAAVI MVA-C; DNA plasmid vaccine with <i>gag, RT, tat, nef, env</i>	C
Ad26.ENVA.01	Apr-08	IPCAVD, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Crucell	US	48	Recombinant adenovirus serotype 26 (rAd26) vaccine	A
IAVI C004/DHO-614	Oct-07	ADARC, Rockefeller University, Gates Foundation, IAVI, Ichor Medical Systems Incorporated	US	40	Serial administration of ADVAX, ADVAX e/g + ADVAX p/n-t, by Ichor TriGrid™ in vivo electroporation. The ADVAX vaccine contains two vectors: ADVAX e/g, with <i>env</i> and <i>gag</i> , and ADVAXp/n-t with <i>pol</i> and <i>nef-tat</i> .	C
HVTN 070	Oct-07	NIAID, HVTN, UPenn/Wyeth	US	120	PENNVAX-B alone, in combination with IL-12, or with 2 different doses of IL-15	B
HVTN 072	Aug-07	NIAID, HVTN, VRC	US	17	DNA and Adenovirus 5 or 35 vectors, all with <i>env</i> in varying prime-boost combinations	A
HVTN 071 [As of Sept 07 enrollment and vaccinations have been discontinued]	Jul-07	NIAID, HVTN, Merck	US	35	Adenovirus 5 vector with <i>gag, pol, nef</i>	B
DVP-1	May-07	St. Jude's Children's Research Hospital	US	20	Prime-boost regimen with <i>PolyEnv, EnvPro, EnvDNA</i>	A, B, C, D, E
VRC 012	May-07	NIAID, VRC	US	35	HIV-1 adenovirus vector vaccine VRC-HIVADV027-00VP: dose escalation and prime-boost with an HIV-1 adenovirus vector vaccine, VRC-HIVADV038-00-VP	A
HVTN 067	Apr-07	NIAID, HVTN, Pharmexa-Epimmune, Bavarian Nordic	US	108	DNA Vaccine EP-1233 and recombinant MVA-HIV polytope vaccine MVA-mBN32, separately and in a combined prime-boost regimen	B A, B, C, D, E, G
HVTN 069	Nov-06	NIAID, HVTN, VRC, NY Blood Center, IMPACTA	US, Peru	90	Prime: DNA vaccine with <i>gag, pol, nef + env</i> Boost: Adenovirus 5 vector with <i>gag, pol + env</i> (intramuscularly, intradermally, subcutaneously)	A,B,C
DHO-0586	Oct-06	ADARC, IAVI	US	8	ADMVA with <i>env/gag-pol, nef-tat</i>	C
HPTN 027	Oct-06	Makerere University, Johns Hopkins University	Uganda	60	Canarypox viral vector with <i>env</i> and <i>gag-pol</i>	B
C86P1	Sep-06	SGUL, Richmond Pharmacology, Novartis Vaccines	UK	31	Prime: HIV gp140 with LTK63 Boost: HIV gp140 with MF59	B
VRC 011	Apr-06	NIAID, VRC	US	60	DNA vaccine with <i>gag, pol, nef + env</i> or Adenovirus vector with <i>gag, pol + env</i>	A, B, C
HVTN 065	Apr-06	NIAID, HVTN, GeoVax	US	120	Prime: DNA plasmid with <i>gag, pro, RT, env, tat, rev, vpu</i> Boost: MVA vector with <i>gag, pol, env</i>	B
HVRF-380-131004	Mar-06	Moscow Institute of Immunology, Russian Federation Ministry of Education and Science	Russian Federation	15	VICHREPOL with polyoxidonium adjuvant	B
HVTN 068	Feb-06	NIAID, HVTN, VRC	US	66	DNAprime/AD boost vs. Ad prime/Ad boost	A, B, C
HIVIS 02	Jan-06	Karolinska Institute, Swedish Institute for Infectious Disease Control, MHRP	Sweden	38	Modified vaccinia Ankara (MVA) viral vector with <i>env, gag, and pol</i> to volunteers from HIVIS 01	A, E
RV 158	Nov-05	MHRP, NIH	US, Thailand	48	Modified vaccinia Ankara (MVA) viral vector with gp160, <i>gag</i> and <i>pol</i>	A, E
EnvDNA	May-05	St. Jude's Children's Research Hospital	US	6	Recombinant HIV-1 multi-envelope DNA plasmid vaccine with <i>env</i>	A, B, C, D, E
RV 156 A	Nov-04	NIAID, HVTN, VRC, MHRP, Makerere U.	Uganda	30	VRC-HIVADV014-00-VP alone or as a boost to VRC-HIVADV009-00-VP	A, B, C
EnvPro	Jun-03	St. Jude's Children's Research Hospital	US	9	Recombinant Purified HIV-1 Envelope Protein Vaccine	D

ADARC: Aaron Diamond AIDS Research Center

ANRS: Agence Nationale de Recherches sur le Sida (France)

HVTN: HIV Vaccine Trials Network

IAVI: International AIDS Vaccine Initiative

IPCAVD: Integrated Preclinical/Clinical AIDS Vaccine Development

MHRP: United States Military HIV Research Program

MoPH: Ministry of Public Health

MUCHS: Muhimbili University College of Health Sciences

NIAID: National Institute of Allergy and Infectious Diseases

NIH: National Institutes of Health

SAAVI: South African AIDS Vaccine Initiative

SGUL: St. George's, University of London

SMI: Swedish Institute for Infectious Disease Control

VRC: Vaccine Research Center